131 related articles for article (PubMed ID: 34918117)
1. JKAP serves as a potential biomarker for the evaluation of inflammatory condition, disease activity, and treatment response to TNF inhibitor in ankylosing spondylitis patients.
Zhou X; Li M
Mod Rheumatol; 2022 Apr; 32(3):613-618. PubMed ID: 34918117
[TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA intersectin 1-2 gradually declines during adalimumab treatment, and its reduction correlates with treatment efficacy in patients with ankylosing spondylitis.
Li M; Zhou X
Inflammopharmacology; 2021 Oct; 29(5):1371-1378. PubMed ID: 34406596
[TBL] [Abstract][Full Text] [Related]
3. MALT1 positively relates to Th17 cells, inflammation/activity degree, and its decrement along with treatment reflects TNF inhibitor response in ankylosing spondylitis patients.
Yuan J; Xiang L; Wang F; Zhang L; Liu G; Chang X; Zhang A; Tao Y
J Clin Lab Anal; 2022 Jul; 36(7):e24472. PubMed ID: 35622982
[TBL] [Abstract][Full Text] [Related]
4. Measurement of pre-treatment inflammatory cytokine levels is valuable for prediction of treatment efficacy to tumor necrosis factor inhibitor in axial spondyloarthritis patients.
Peng F; Chen F; Wen H; Bai J; Tian Y
Int J Rheum Dis; 2022 Aug; 25(8):844-850. PubMed ID: 35694730
[TBL] [Abstract][Full Text] [Related]
5. Circulating JNK pathway-associated phosphatase level correlates with decreased risk, activity, inflammation level and reduced clinical response to tumor necrosis factor-α inhibitor in Crohn disease patients.
Shi X; Yang W; Wang N; Zhu J
Medicine (Baltimore); 2019 Aug; 98(33):e16622. PubMed ID: 31415355
[TBL] [Abstract][Full Text] [Related]
6. Predictive values of circulating miR-146a and miR-155 for disease activity and clinical response to TNF-α blocking therapy in patients with ankylosing spondylitis.
Liu L; Hu X
Int J Rheum Dis; 2024 Jan; 27(1):e15004. PubMed ID: 38152051
[TBL] [Abstract][Full Text] [Related]
7. PBMC CDC42 reveals the disease activity and treatment efficacy of TNF inhibitor in patients with ankylosing spondylitis.
Zhang Q; Jin D; Mou X; Ye H
J Clin Lab Anal; 2022 Mar; 36(3):e24267. PubMed ID: 35104386
[TBL] [Abstract][Full Text] [Related]
8. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A
Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401
[TBL] [Abstract][Full Text] [Related]
9. Predictive Values of Blood Type I and Type II Interferon Production for Disease Activity and Clinical Response to TNF-α Blocking Therapy in Patients with Ankylosing Spondylitis.
Hu Y; Lou B; Jiang Z; Yu C
Tohoku J Exp Med; 2023 Jul; 260(3):263-271. PubMed ID: 37081619
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.
Rudwaleit M; Claudepierre P; Wordsworth P; Cortina EL; Sieper J; Kron M; Carcereri-De-Prati R; Kupper H; Kary S
J Rheumatol; 2009 Apr; 36(4):801-8. PubMed ID: 19273449
[TBL] [Abstract][Full Text] [Related]
11. Serum interα-trypsin inhibitor heavy chain H4 may be an anti-inflammatory marker reflecting disease risk, activity and treatment outcome of ankylosing spondylitis.
Sun Z; Zhang Y; Zhou H; Li J; Zhou Y; Wang L
Scand J Clin Lab Invest; 2023 Dec; 83(8):540-547. PubMed ID: 38156824
[TBL] [Abstract][Full Text] [Related]
12. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
14. JNK pathway-associated phosphatase illustrates low expression and negative correlations with inflammation, disease activity, and T-helper 17 cells in inflammatory bowel disease children.
Wang C; Bai C; Mao C; Leng X; Wang F; Guo X
J Clin Lab Anal; 2022 Sep; 36(9):e24488. PubMed ID: 35908771
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
Callhoff J; Sieper J; Weiß A; Zink A; Listing J
Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
[TBL] [Abstract][Full Text] [Related]
16. Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study.
Nam B; Koo BS; Lee TH; Shin JH; Kim JJ; Lee S; Joo KB; Kim TH
BMC Musculoskelet Disord; 2021 Feb; 22(1):140. PubMed ID: 33541326
[TBL] [Abstract][Full Text] [Related]
17. Reproducibility of the Bath Ankylosing Spondylitis Indices of disease activity (BASDAI), functional status (BASFI) and overall well-being (BAS-G) in anti-tumour necrosis factor-treated spondyloarthropathy patients.
Madsen OR; Rytter A; Hansen LB; Suetta C; Egsmose C
Clin Rheumatol; 2010 Aug; 29(8):849-54. PubMed ID: 20306214
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of serum JKAP in acute ischemic stroke patients.
Zhang J; Yang J; Hu J; Zhao W
J Clin Lab Anal; 2022 Apr; 36(4):e24270. PubMed ID: 35274367
[TBL] [Abstract][Full Text] [Related]
19. The correlation between Jun N-terminal kinase pathway-associated phosphatase and Th1 cell or Th17 cell in sepsis and their potential roles in clinical sepsis management.
Yu D; Peng X; Li P
Ir J Med Sci; 2021 Aug; 190(3):1173-1181. PubMed ID: 33083958
[TBL] [Abstract][Full Text] [Related]
20. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.
Lord PA; Farragher TM; Lunt M; Watson KD; Symmons DP; Hyrich KL;
Rheumatology (Oxford); 2010 Mar; 49(3):563-70. PubMed ID: 20032223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
